227 related articles for article (PubMed ID: 37511766)
1. Mid-Regional Pro-Adrenomedullin and N-Terminal Pro-B-Type Natriuretic Peptide Measurement: A Multimarker Approach to Diagnosis and Prognosis in Acute Heart Failure.
Spoto S; Argemi J; Di Costanzo R; Gavira Gomez JJ; Salterain Gonzales N; Basili S; Cangemi R; Abbate A; Locorriere L; Masini F; Testorio G; Calarco R; Battifoglia G; Mangiacapra F; Fogolari M; Costantino S; Angeletti S
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511766
[TBL] [Abstract][Full Text] [Related]
2. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
3. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
[TBL] [Abstract][Full Text] [Related]
5. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
6. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
8. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
9. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study.
Potocki M; Breidthardt T; Reichlin T; Morgenthaler NG; Bergmann A; Noveanu M; Schaub N; Uthoff H; Freidank H; Buser L; Bingisser R; Christ M; Mebazaa A; Mueller C
Crit Care; 2009; 13(4):R122. PubMed ID: 19627611
[TBL] [Abstract][Full Text] [Related]
10. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
11. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pro-adrenomedullin and NT-proBNP in patients referred from the emergency department with influenza syndrome.
Valero Cifuentes S; García Villalba E; Alcaraz García A; Alcaraz García MJ; Muñoz Pérez Á; Piñera Salmerón P; Bernal Morell E
Emergencias; 2019 Jun; 31(3):180-184. PubMed ID: 31210450
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
16. Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
Kuan WS; Ibrahim I; Chan SP; Li Z; Liew OW; Frampton C; Troughton R; Pemberton CJ; Chong JPC; Tan LL; Lin W; Ooi SBS; Richards AM
Eur J Heart Fail; 2020 Apr; 22(4):692-700. PubMed ID: 31808279
[TBL] [Abstract][Full Text] [Related]
17. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure.
Chen X; Wu M; Xu K; Huang M; Zhuo X
Acta Cardiol; 2021 Feb; 76(1):87-92. PubMed ID: 32519930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
